After a hard-fought victory to legalise medical cannabis in the UK, why is it still so hard to access?
The Guardian
Overall Assessment
The article effectively uses a human-interest narrative to highlight systemic failures in UK healthcare policy regarding medical cannabis access. It provides strong historical and statistical context but leans toward advocacy, with limited representation of institutional or medical perspectives. The tone is empathetic and critical of policy implementation, culminating in a call for broader drug policy reform.
"For our future wellbeing as a society, we need to think seriously about how we design a post-prohibition framework for regulating drugs."
Editorializing
Headline & Lead 90/100
The article examines the disparity between the legalisation of medical cannabis in the UK and its limited accessibility through the NHS, using the personal story of campaigner Hannah Deacon and her son Alfie to highlight systemic failures in healthcare policy and implementation. It provides historical context, policy analysis, and critique of the growing private medical cannabis industry, while maintaining a generally empathetic yet critical tone. Despite strong narrative focus and sourcing, the piece leans toward advocacy, particularly in its conclusion, urging structural reform in drug policy.
✓ Balanced Reporting: The headline poses a legitimate and newsworthy question that reflects the core issue explored in the article — the gap between legalisation and access to medical cannabis. It avoids hyperbole and is directly tied to the narrative.
"After a hard-fought victory to legalise medical cannabis in the UK, why is it still so hard to access?"
Language & Tone 75/100
The article examines the disparity between the legalisation of medical cannabis in the UK and its limited accessibility through the NHS, using the personal story of campaigner Hannah Deacon and her son Alfie to highlight systemic failures in healthcare policy and implementation. It provides historical context, policy analysis, and critique of the growing private medical cannabis industry, while maintaining a generally empathetic yet critical tone. Despite strong narrative focus and sourcing, the piece leans toward advocacy, particularly in its conclusion, urging structural reform in drug policy.
✕ Appeal To Emotion: The article uses emotionally charged language to describe Alfie’s seizures and Deacon’s desperation, which, while factual, amplifies emotional impact over neutral reporting.
"I remember one particular night when we were holding him down,” she recalled. “I think the doctor tried 10 times to get a needle into his hand and he was screaming and screaming and crying ‘Mummy!’ It was really traumatic.”"
✕ Loaded Language: Phrases like 'fucking terrifying' and 'they changed the law to shut me up' are presented without counterbalancing institutional voices, contributing to a tone of frustration and distrust.
"It was fucking terrifying, the most terrifying thing I’ve ever done,” Deacon recalled..."
✕ Editorializing: The conclusion advocates for a specific policy direction — a post-prohibition framework — which moves beyond reporting into editorial stance.
"For our future wellbeing as a society, we need to think seriously about how we design a post-prohibition framework for regulating drugs."
Balance 80/100
The article examines the disparity between the legalisation of medical cannabis in the UK and its limited accessibility through the NHS, using the personal story of campaigner Hannah Deacon and her son Alfie to highlight systemic failures in healthcare policy and implementation. It provides historical context, policy analysis, and critique of the growing private medical cannabis industry, while maintaining a generally empathetic yet critical tone. Despite strong narrative focus and sourcing, the piece leans toward advocacy, particularly in its conclusion, urging structural reform in drug policy.
✕ Cherry Picking: The article relies heavily on the personal narrative of Hannah Deacon, which is powerful but represents a single perspective. While other voices are mentioned (e.g., Charlotte Caldwell, Oliver Robinson), they are not quoted directly or given equal space, creating a slight imbalance in lived experience representation.
"Hannah Deacon said. “They would periodically take him off life support to see if he would stop seizing, but he wouldn’t, so they would put him back on.”"
✕ Vague Attribution: Medical professionals are represented through anecdotal accounts (e.g., the doctor threatening to report Deacon to social services), but no current NHS clinician or policy expert is quoted to provide institutional perspective, limiting balance.
"One day, after Deacon asked one particular doctor again about cannabis as an alternative treatment, he put down his pen, peered over at her and muttered: “If you speak to me again about cannabis, I am going to report you to social services.”"
✓ Proper Attribution: The article includes historical sourcing (O’Shaughnessy, East India Company) and modern data (NHS Business Service Authority, ITV News), showing effort to ground claims in credible institutions.
"According to the NHS Business Service Authority, a total of 89,239 prescriptions for unlicensed cannabis medicines were issued between November 2018 and July 2022, but fewer than five of these prescriptions were issued by the NHS."
Completeness 95/100
The article examines the disparity between the legalisation of medical cannabis in the UK and its limited accessibility through the NHS, using the personal story of campaigner Hannah Deacon and her son Alfie to highlight systemic failures in healthcare policy and implementation. It provides historical context, policy analysis, and critique of the growing private medical cannabis industry, while maintaining a generally empathetic yet critical tone. Despite strong narrative focus and sourcing, the piece leans toward advocacy, particularly in its conclusion, urging structural reform in drug policy.
✓ Comprehensive Sourcing: The article includes extensive historical background on cannabis use in British India and the role of William O’Shaughnessy, which enriches the context and shows the long-standing medical interest in cannabis — a rare depth in mainstream reporting.
"William O’Shaughnessy is remembered as one of the great medical innovators of the Victorian age, celebrated for his contributions to the treatment of cholera, by developing an early form of intravenous rehydration."
✓ Proper Attribution: It contextualises the current state of medical cannabis access by citing specific data on prescriptions — 89,239 unlicensed prescriptions issued between 2018 and 2022, with fewer than five funded by the NHS — which grounds the narrative in verifiable figures.
"According to the NHS Business Service Authority, a total of 89,239 prescriptions for unlicensed cannabis medicines were issued between November 2018 and July 2022, but fewer than five of these prescriptions were issued by the NHS."
✓ Comprehensive Sourcing: The article addresses the complexity of regulatory and institutional barriers, including Nice guidelines, licensing requirements, and clinician training gaps, providing a systemic rather than individualised explanation for access issues.
"Making a medication legal isn’t enough to get the doctors to prescribe it to patients. It needs a licence, which is usually obtained after verified clinical trials."
Medical cannabis portrayed as scientifically valid and morally legitimate treatment
Historical context (O’Shaughnessy), successful patient outcomes (Alfie, Billy), and critique of outdated stigma all serve to legitimise cannabis as medicine.
"O’Shaughnessy revealed the potential of cannabis in pain management. His investigations also found that cannabis was particularly useful in treating “convulsion disorders” – or what we now call epilepsy."
NHS portrayed as failing to implement life-saving treatment due to systemic inertia and underfunding
The article repeatedly highlights institutional resistance, lack of clinician training, and bureaucratic barriers preventing access to medical cannabis despite legalisation. Framing focuses on systemic failure rather than individual shortcomings.
"Making a medication legal isn’t enough to get the doctors to prescribe it to patients. It needs a licence, which is usually obtained after verified clinical trials. Then, once it gets its licence, Nice, the UK’s National Institute for Health and Care Excellence, which provides guidance on medication and cost effectiveness, should include the medication as one of its recommended options from which NHS doctors can select."
Deacon framed as a courageous advocate excluded by institutions but morally included in public discourse
Cherry-picked personal narrative and appeal to emotion elevate Deacon as a sympathetic figure fighting an unjust system, reinforcing her moral authority.
"I just thought, sod this. He’s going to die if I don’t do something. So I found my voice, perhaps for the first time in my life. I stood up for myself and my family."
Government portrayed as disingenuous, changing laws for PR rather than genuine reform
Loaded language and direct quotes imply bad faith, particularly the claim that the law was changed 'to shut me up,' suggesting symbolic action without real commitment.
"They changed the law to shut me up,” she told me."
Private medical cannabis industry framed as profit-driven, exacerbating inequality
The article critiques the growth of private clinics while NHS access remains minimal, linking expansion to market forces rather than patient need.
"And few things illustrate this two-tier system more clearly than the way medical cannabis has been rolled out since 2018."
The article effectively uses a human-interest narrative to highlight systemic failures in UK healthcare policy regarding medical cannabis access. It provides strong historical and statistical context but leans toward advocacy, with limited representation of institutional or medical perspectives. The tone is empathetic and critical of policy implementation, culminating in a call for broader drug policy reform.
Since medical cannabis was reclassified in 2018, very few prescriptions have been issued through the NHS, with most patients accessing treatment privately. Barriers include lack of clinician training, absence of licensed products, and restrictive funding. Campaigners argue the policy change has not translated into equitable patient access.
The Guardian — Lifestyle - Health
Based on the last 60 days of articles
The Guardian
No related content